ArticleJournal of gastric cancer2026
Prognostic Value of Early Weight Gain in Patients With Stage IV Gastric Cancer Undergoing First-Line Combination Immunotherapy.
Article in Journal of gastric cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeConventional radiologic assessment using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) may not fully capture clinical responses during immunotherapy. Therefore, we investigated the association between early weight gain (WG) and prognosis in this population. MATERIALS AND
methodsWe enrolled 268 consecutive patients with stage IV gastric cancer (GC) who received first-line combination immunotherapy. Data were obtained from a prospective clinical database. Cox regression and g-computation were used to quantify and visualize the associations between WG and progression-free survival (PFS) and overall survival (OS). The skeletal muscle index (SMI), subcutaneous fat index (SFI), and visceral fat index (VFI) at L3 were calculated using 3D Slicer.
resultsAfter a median follow-up of 29.7 months, 210 (78.3%) patients experienced disease progression and 185 (69.0%) died. The median overall survival (mOS) was 14.8 months, and the median progression-free survival (mPFS) was 7.2 months. The optimal cutoff value for WG was 4%, classifying patients into the WG ≥4% (n=87) and WG <4% (n=181) groups. WG ≥4% was associated with longer mOS (hazard ratio [HR], 0.225; P<0.001) and mPFS (HR, 0.449; P<0.001). WG ≥4% was also significantly associated with prolonged mOS in patients with stable disease (SD) (HR, 0.140; P<0.001) and progressive disease (PD) (HR, 0.045; P=0.003). Multivariate Cox regression analysis confirmed WG as an independent predictor of survival outcomes. SFI (r=0.34) and SMI (r=0.32) were moderately and positively correlated with OS.
conclusionsWG ≥4% is associated with better survival outcomes in patients with stage IV GC undergoing combination immunotherapy, even in those with SD or PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.